Table 2.
Therapy prior to inclusion in early-phase trial cohort (n=136 of 383)
| Protocol | Treatment | Number of patients |
|---|---|---|
| Frontline therapy | ||
| 321P3 | Autologous purged BMT after induction and conditioning with etoposide, cisplatin, and TBI | 1 |
| P9641 | Surgery, observation; salvage chemotherapy | 5 |
| A3961 | 4–8 cycles of carboplatinum, etoposide, cyclophosphamide, doxorubicin | 2 |
| A3973 | Purged v. Unpurged PBSC Transplant after Dose Intensive Induction Therapy | 57 |
| ANBL00P1 | Tandem High Dose Chemotherapy with Stem Cell Rescue Following Induction | 2 |
| ANBL02P1 | Induction Incorporating Dose-Intensive Topotecan and Cyclophosphamide | 6 |
| ANBL0531 | 2–8 cycles of chemotherapy | 1 |
| ANBL0532 | Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy | 24 |
| Maintenance therapy | ||
| ANBL0032 | chimeric antibody 14.18 (Ch14.18), GM-CSF, IL-2, and Isotretinoin | 42 |
| ANBL0931 | chimeric antibody 14.18 (Ch14.18), GM-CSF, IL-2, and Isotretinoin | 2 |
| Phase 1 or 2 therapy | ||
| P9761 | irinotecan | 2 |
| P9462 | Topotecan, cyclophosphamide | 5 |
| A0935A | ch14.18 with GM-CSF, IL-2 in GD2 Positive Malignancies post ABMT or PBSC Rescue | 2 |
| ADVL0018 | hu14.18-IL2 Fusion Protein in Patients with GD2 Expressing Tumors | 6 |
| ADVL0016 | ZD1839 IressaTM, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 1 |
| ADVL0921 | MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor | 8 |
| ADVL1011 | JAK Inhibition with Ruxolitinib | 4 |
| ANBL1021 | hu14.18-IL2 immunocytokine + GM-CSF and Isotretinoin | 8 |